Since EGFR is known to mitigate its signaling through PI3K-Akt and RAS, loss of DHHC20 or a palmitoyl-resistant EGFR significantly reduces their oncogenic signaling and downstream Myc in a mouse model of oncogenic KRAS-driven lung adenocarcinoma and subsequently affects tumor growth both in vitro and in vivo (45, 46). The gene discussed is EGFR; the disease is lung adenocarcinoma.